Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis; Co. Reports 'Randomized, double-blind, placebo-controlled study did not meet the primary endpoint'